Clinical Trial Update: A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer [Phase 3]

View source ↗

Summary

A Phase III clinical trial evaluating BNT324 versus docetaxel in metastatic castration-resistant prostate cancer is listed as not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• BNT324
• DOCETAXEL (DOCETAXEL)

Snippet

Sponsor: BioNTech SE | Conditions: Metastatic Castration-resistant Prostate Cancer | Phase 3 | Status: NOT_YET_RECRUITING